Autoimmune's core strategy in the field of phytopharmaceuticals has been to develop value-added products that can be marketed in over-the-counter and prescription categories.

Autoimmune focuses its R&D discovery efforts on common cancers, infectious diseases, cardiovascular and other lifestyle diseases which represent a massive and steady demand in the Malaysian and world markets.

We retain full rights to all our discoveries.

Universities and other independent entities are appointed to undertake pre-clinical tests and verify the medicinal potential of our novel botanical based extracts.

We continue to explore new methods of discovery and development at the same time seeking strategic partners for product development, commercialization or other avenues. We have also established joint-ventures with research institutes, universities and hospitals.

Some of our compounds may be out-licensed to multinational pharmaceutical companies to complete the health regulatory approval process before being marketed globally.

i. Invent & identify potential products with supporting scientific data.

ii. Value-add products by extending data through pre-clinical and clinical trials.

iii. Out-license selected products to late stage clinical trials and registration processes, or commercialize to major pharmaceutical companies.

Income from out-licensing deals is derived in the form of:

• up front fees - typically paid at the time of signing a contract;
• milestone payments - paid as significant progress is made; and
• royalties on sales - paid as sales revenue is generated.